Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Danirixin (GSK1325756) is a potent antagonist of CXCR2 that inhibits IL-8 binding to CXCR2 (IC50: 12.5 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 80.00 | |
5 mg | In stock | $ 247.00 | |
10 mg | In stock | $ 348.00 | |
25 mg | In stock | $ 588.00 | |
50 mg | In stock | $ 838.00 | |
100 mg | In stock | $ 1,160.00 | |
500 mg | In stock | $ 2,320.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 278.00 |
Description | Danirixin (GSK1325756) is a potent antagonist of CXCR2 that inhibits IL-8 binding to CXCR2 (IC50: 12.5 nM). |
Targets&IC50 | CXCL8-CXCR2:12.5 nM (cell free) |
In vivo | Systemic exposure following single doses of danirixin 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg increased with increasing dose. Engagement of pharmacology was demonstrated as inhibition of ex-vivo CXCL1-induced CD11b expression on peripheral blood neutrophils when compared to placebo (approximately 50 % for 50 mg and 100 mg danirixin, and 72 % at 200 mg). There was a 37 % decrease in Cmax and a 16 % decrease in AUC (0-∞) following administration of danirixin in the presence of food. Cmax also decreased by 65 % when danirixin 100 mg was administered following omeprazole 40 mg once daily for 5 days [1]. |
Synonyms | GSK1325756 |
Molecular Weight | 441.9 |
Formula | C19H21ClFN3O4S |
CAS No. | 954126-98-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 8 mg/mL (18.10 mM), Sonification and heating are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Danirixin 954126-98-8 Autophagy GPCR/G Protein Immunology/Inflammation CXCR Inhibitor inhibit GSK-1325756 GSK 1325756 CXC chemokine receptors GSK1325756 inhibitor